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Repetitive transcranial magnetic stimulation (rTMS) is a popular and effective treatment for drug resistant depression. However, there 
is considerable variability in clinical outcomes, in previous studies and between patients. Because of high requirements for the use of 
fMRI based neuronavigation, many practitioners of rTMS still choose to use a standard 5 cm rule for rTMS coil placement which leads to 
large variations in which brain regions are being stimulated. We decided to test the possibilities of a MNI based MR‑less neuronavigation 
system in rTMS depression treatment, by comparing the physiological effects and clinical outcomes of 3 distinct stimulation targets. 
Forty‑six patients (thirty‑three female, thirteen male) from the Republican Vilnius psychiatric hospital, all with drug resistant depressive 
disorder, participated in the study. All patients received high frequency (10 Hz) stimulation for 10 to 15 daily rTMS sessions. However, 
before the treatment they were randomly sorted into 3 groups according to stimulation target in MNI map: Group 1 received rTMS 
at point ‑40; 48; 35; Group 2 received rTMS at point ‑46; 45; 38; Group 3 received rTMS at point ‑38; 44; 26. Electroencephalography 
(EEG) recordings and clinical tests were obtained the day before the rTMS course and after the last session. There were some notable 
differences in physiological changes between the groups, with the largest EEG band spectral power increases found in Group 1 patients 
and the lowest in Group 2 patients. There was a significantly larger decrease of the Hamilton Depression Rating Scale (HAM‑D) scores in 
the Group 3 (66.94%) compared to Group 1 (57.52%) and Group 2 (56.02%). This suggests it is possible to achieve higher clinical efficacy 
and less physiological impact on the brain when using different targets in a neuronavigated MNI based MR‑less rTMS system.
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INTRODUCTION
According to the World Health Organization around 
350 million of people suffer from depression world‑
wide (Morvai et al. 2016). However, less than one third 
of depression patients reach remission after 12 weeks 
of initial pharmacological treatment (Trivedi et al. 
2006), some produce unwanted side effects (Teng et al. 
2017), whilst around 30% of major depressive disorder 
patients are diagnosed with drug treatment resistant 
disorder (Bewernick and Schlaepfer 2015, Fitzgerald 
et al. 2003, Silverstein et al. 2015). Currently, depres‑
sion which fails to find a pharmacological treatment is 
treated with repetitive transcranial magnetic stimula‑
tion (rTMS), which has proven itself to be clinically ef‑
fective in drug resistant depression therapy, surpassing 
the placebo effect (Avery et al. 2006, Blumbergeret al. 
2016, Concerto et al. 2015, Filipcic et al. 2017, Fitzger‑
ald et al. 2003, Kito et al. 2016, O’Reardon et al. 2007, 
Sehatzedeh et al. 2016, Teng et al. 2017). However, the 
therapeutic effect of rTMS therapy tends to vary sig‑
nificantly between studies and between individuals, 
even when similar protocols are applied, so there is 
a strong need for better optimization of rTMS parame‑
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ters as well as better insights into possible therapeutic 
markers (Kobayashi et al. 2017, Luber et al. 2017, Zyss 
et al. 2015). 
With rTMS pulse parameters being standardized 
and easily replicated in multiple cases, and with stimu‑
lation intensities being tailored to the individual motor 
threshold values, most technical variability should arise 
from differences in coil placement over the brain. Since 
its origin as a treatment for depression, the coil place‑
ment in the clinical rTMS application has been a stan‑
dard or blind protocol which attributes left hemisphere 
prefrontal dorsolateral cortex (DLPFC) to a fixed point 
5 to 6 cm anterior of a right hand thumb muscle mo‑
tor area (Ahdab et al. 2010). However, since individual 
brain size and shape can vary significantly, this method 
leads to a great dispersion of actual stimulation targets 
(Luber et al. 2017, Mir‑Moghtadaei et al. 2015, Pommier 
et al. 2017) and therefore can severely limit efficacy. 
Studies have shown that when using 5 cm standard coil 
positioning rule, up to 68% of patient cases might actu‑
ally result in a miss of the DLPFC area, instead hitting 
the dorsolateral premotor cortex or orbitofrontal cor‑
tex (Herwig et al. 2001, Luber et al. 2017). Based on the 
fact that the focality of a typical figure of eight TMS 
coil is modeled to be around 5 cm2 (Deng et al, 2013, 
Thielscher and Kammer 2004), it could be that the ap‑
plication of a standard 5 cm anterior to the motor cor‑
tex rule yields a great variety of clinical responses in 
different patients and studies as it does not take in ac‑
count absolute differences in head anatomy (George et 
al. 2013) and thus results in administering the most ef‑
fective stimulation to different cerebral areas for each 
patient. Currently the highest precision in anatomical‑
ly and physiologically based stimulation targeting can 
be achieved when using findings of functional brain 
imaging studies together with precision neuronaviga‑
tion tracking (Luber et al. 2017, Mir‑Moghtadaei et al. 
2015). The best results can be achieved with individual 
measurements and better insights into antidepressant 
rTMS mechanisms through research.
Another important piece of the rTMS therapy puzzle 
is finding the most suitable biomarkers to help predict 
the clinical response and better understand the mech‑
anisms underlying antidepressant rTMS treatment. 
Suggested markers range from quantitative changes in 
brain activity, measured by simple baseline electroen‑
cephalography (EEG) or baseline functional magnetic 
resonance imaging (fMRI); to specific cognitive priming 
or functional connectivity studies, using complex algo‑
rithms and integrated systems; to studies of molecular 
factors and individual gene polymorphisms (Kito et al. 
2016, Kobayashi et al. 2017, Luber et al. 2017, Noh 2016, 
Sale et al. 2015, Silverstein et al. 2015). Major depressive 
disorder is usually characterized by functional impair‑
ments in the fronto‑mezo‑lymbic system network (Pulcu 
et al. 2014), manifesting itself in asymmetry of activi‑
ty in the prefrontal cortex between brain hemispheres 
(Henriques and Davidson 1991, Lubar et al. 2003) and an 
increase of metabolic activity in the subgenual anterior 
cingulate (Mayberg et al. 2000, 2005). Since individual 
fMRI is often found to be too expensive and complicated 
to be used in a daily clinical rTMS practice, many stud‑
ies into the treatment of depression with rTMS mark‑
ers are carried out using separate EEG systems or inte‑
grated rTMS‑EEG systems. Experiments support the use 
of EEG in various TMS studies as a reliable indicator of 
cortical excitability changes, as EEG activity is a sensi‑
tive measure to subtle TMS induced changes (Canali et 
al. 2014, Thut and Pascual‑Leone 2010), ranging from 
short event‑related potential (ERP) like phenomenon to 
a more robust long‑term potentiation/depression (LTP/
LTD) based change, especially in the motor and prefron‑
tal cortices (Lioumis et al. 2009). Previously, much em‑
phasis was placed on the frontal alpha band asymmetry 
theory (Henriques and Davidson 1991). However, later 
studies have proved it to be of limited diagnostic value 
with a high degree of variability (Funk and George 2008, 
van der Vinne et al. 2017). As in the studies examining 
the clinical effectiveness of rTMS, studies examining the 
effect of rTMS on EEG have also been quite variable, and 
are hard to replicate beyond the original study popula‑
tion (Widge et al. 2013). When various authors have tried 
to measure a basic rTMS effect on EEG profile, many have 
failed to find consistent changes in alpha band power, 
supporting the alpha asymmetry theory. Some have 
found a notable increase of alpha power in the occipital 
area (Melnikova et al. 2015), whilst others have observed 
no alpha band power change at all (Funk and George 
2008, Loo et al. 2001, Spronk et al. 2008). The most ro‑
bust baseline EEG findings were an increase in slow delta 
wave power after prefrontal cortex rTMS (Griškova et al. 
2006, Spronk et al. 2008, Valiulis et al. 2012). Increased 
delta band power has also been observed after rTMS ap‑
plication over the motor cortex (Assenza et al. 2015) and 
after depression treatment with electroconvulsive ther‑
apy (ECT) (Sackeim et al. 1996). However, no cases, ex‑
cept for the delta increase in the prefrontal cortex after 
ECT (Sackeim et al. 1996), have produced significant cor‑
relations with clinical changes. It seems that the rise in 
delta band power, although not clearly related to any un‑
derlying depression mechanisms and therefore of ques‑
tionable therapeutic value, can be regarded as a physio‑
logical stamp of the impact of rTMS on the brain. While 
some EEG variability might arise from differences in the 
time between the rTMS procedure and EEG recording 
(Thut and Pascual‑Leone 2010) (many EEG changes tend 
to return to the baseline after 15–70 minutes) the delta 
power changes can be very robust and long lasting (Vali‑
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ulis 2014), even after a complete therapy course. There‑
fore, the question remains; could delta power changes 
also be influenced and probably minimized by TMS coil 
placement precision? 
If we assume that rTMS can restore or optimize neu‑
ral activity from a pathological state (Paus and Barret 
2004, Sale et al. 2015) by hitting the right target with the 
right stimulus parameters, we should at all costs avoid 
oversimplification of our therapeutic models and always 
take into account, not just the activity of a target region, 
but rather the state of the whole neural network (Fox et 
al. 2012). Although traditional rTMS coils are unable to 
reach and therefore alter the activation of subcortical 
areas relevant for depression treatment like the subgen‑
ual cingulate directly, this could be achieved in an effec‑
tive manner when targeting cortical network areas with 
the strongest possible connectivity. Generally, left hemi‑
spheric prefrontal cortex areas have a notable function‑
al connection to the fronto‑mezo‑limbic system, includ‑
ing deeper limbic areas (Padberg and George 2009). How‑
ever, not all rTMS therapy neuroimaging studies show 
equal strength of this connection measured by changes 
in the subgenual cingulate (Kito et al. 2011). It puts an 
additional interest in high precision rTMS targeting, 
based on individual cortical‑subcortical connectivity 
evaluation. Since neuronavigated rTMS coils theoreti‑
cally can be placed with an accuracy of less than 1 mm 
over the cortical target, it would makes sense to find an 
exact point of the left DLPFC with the strongest connec‑
tion to the subgenual cingulate (Fox et al. 2013).
Literature provides several brain coordinates to be 
used as precise rTMS targets in left DLPFC to be used 
in depression therapy. SPECT studies have provided us 
with possible rTMS stimulation target areas based on 
blood perfusion differences (Jha et al. 2016, Teneback 
et al. 1999), by distinguishing blood flow patterns in 
left prefrontal dorsolateral cortex areas of responders 
(‑40; 48; 35;) vs. non responders (Teneback et al. 1999). 
Other possible precise rTMS targets (‑46, 45, 38) can be 
averaged from empirical clinical effectiveness when 
using fMRI based rTMS neuronavigation (Fitzgerald et 
al. 2009b). Fox et al. (2012) argue that the differences 
in clinical effectiveness when stimulating left PFDLC 
might arise from differences of connection strength 
to the subcortical areas. fMRI studies have shown that 
when comparing stimulation of different left DLPFC 
targets to the activity changes of the subgenual cin‑
gulate, the highest negative correlation is found when 
using rTMS target coordinates of ‑38; 44; 26 (Fox et al. 
2013). As such, stimulation placement so to achieve in‑
direct subgenual cingulate activity alteration should 
provide the best clinical results. 
However, despite the enormous potential of neu‑
roimaging studies, the biggest drawback of applying 
ultra‑precise individual fMRI based neuronavigated 
rTMS in clinical practice is the high monetary and time 
costs, given it would require sophisticated equipment 
and solid neuroanatomical skills for operators to iden‑
tify individual targets for each patient (Pommier et al. 
2017). This results in most clinical practitioners still 
using a standard, highly imprecise rTMS coil place‑
ment method, instead of incorporating neuroimaging 
research data findings into their practice. Optional 
Beam F3 method, although more adaptive to head size 
differences, also proves to be less precise than neuro‑
navigation as it is based entirely on head landmarks, 
rather than functional connectivity data (Mir‑Moghta‑
daei et al. 2015, Pommier et al. 2017). Mir‑Moghtadaei 
et al (2015) found that a discrepancy of coil placement 
between MRI‑Guided placement and Beam F3 scalp site 
can vary between 0.65 cm and 1.36 cm for most patients, 
and in some cases this can reach close to 2 cm. Anoth‑
er benefit of neuronavigation systems is an ability to 
accurately track coil positions during the procedure 
in real time. Possible upgrades in this situation could 
be the use of MR‑less MNI model based neuronaviga‑
tion systems, which enable practitioners to place the 
rTMS coils over an exact brain coordinate without the 
need of an individual MRI scan, thus providing less dis‑
persion of stimulation targets than previous methods 
(Pommier et al. 2017) and enabling easy incorporation 
of functional connectivity study findings into a stan‑
dardized semi‑blind design. However, such applications 
are still quite rare. Therefore, in our study we decided 
to compare how different rTMS targets, provided by 
previous neuroimaging studies and applied in the MNI 
model based MR‑less neuronavigation system, would 
affect basic physiological EEG changes in the brain, as 
well as how they would affect clinical outcomes. 
METHODS
Subjects
46 inpatients (33 female, 13 male, mean age 
51.28 years, SD=12.62 years) from the Republican Vil‑
nius psychiatric hospital with drug resistant depres‑
sive disorder (without anxiety symptoms) participated 
in the study. Before the treatment each patient signed 
a written consent. During the rTMS course, previously 
unsuccessful pharmaceutical treatment was continued 
at steady stable doses. None of the patients were treated 
with tricyclic antidepressants. 
Patients were randomly assigned to three groups 
according to stimulation site in the MNI map: Group 
1 (20 patients); Group 2 (11 patients); Group 3 (11 pa‑
tients). 
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All the patients were treated with high frequency 
(10 Hz) rTMS over the left PFDLC. Procedures were car‑
ried out daily, five days per week, for two to three weeks 
(10–15 procedures overall).
Equipment and procedure
TMS procedures were applied using MagVenture 
Magpro X100 TMS stimulator with MagVenture Cool Coil 
B65 liquid cooled figure eight coil. During the stimula‑
tion 280 µs biphasic impulses were used. The rTMS pro‑
tocol consisted of 20.8 second trains of 10 Hz frequen‑
cy impulses, applied at 100% motor threshold intensity 
(1600 impulses overall). 
For neuronavigated coil placement, the Localite 
TMS Navigator MR‑less system was used. This neu‑
ronavigation system utilizes a standard the Montreal 
Neurological Institute (MNI) (MNI ICBM152 non‑linear 
symmetric T1 Average Brain) brain map. MNI brain 
map deformations for each patient head are calculat‑
ed using anatomical markers and points from the head 
surface: 1) root of the nose (nasion); 2) left corner of 
the eye (left exocanthion); 3) right corner of the eye 
(right exocanthion); 4) anterior point on the left audi‑
tory canal (left preauricular point); 5) anterior point 
on the right auditory canal (right preauricular point); 
6) occipital prominence (inion); 7) surface at the back 
of the head from the most posterior point; 8) surface at 
the top of the head from the most superior point. Left 
PFDLC targets were placed in the MNI map according to 
these coordinates: 1) Group 1 ‑40; 48; 35; (Teneback et 
al. 1999); 2) Group 2 ‑46; 45; 38 (Fitzgerald et al. 2009b); 
3) Group 3 ‑38; 44; 26 (Fox et al. 2014) (Fig. 1).
EEG measurement
For EEG recording, EBNeuro Galileo Mizar apparatus 
was used. EEG was recorded before the rTMS course and 
20–30 minutes after the last procedure in an electrically 
shielded booth. Over the head of the patient, 20 round 
bridge type Ag/AgCL electrodes were placed according 
to international 10–20 system and secured with a cap. 
Fig. 1. TMS target coordinates in the MNI brain model for three patient groups.
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Fpz electrode was used as a ground, ear electrodes act‑
ed as a reference.
Electrode impedance was maintained lower than 
5  kΩ.  Resting  state  EEG  was  recorded  for  10  minutes 
with the patient sitting eyes closed. EEG recordings 
were filtered using low frequency (0.53 Hz), high fre‑
quency (70 Hz) and notch (50 Hz) filters. Data was dig‑
itized at 256 frequency 12 bit rate. For further analysis 
30 second EEG intervals without artifacts were used. 
Hanning window was applied for 2 second epochs. EEG 
spectrum S (ω) mean power values (μV2) were calculated 
by fast Fourier transformation (FFT) method. Absolute 
power values were calculated for delta (1.00–3.50 Hz), 
theta (3.50–8.00 Hz), alpha (8.00–12.00 Hz) and beta 
(12.00–32.00 Hz) frequency band intervals.
EEG band power averages for particular brain ar‑
eas were calculated by combining data from these 
electrodes: a) Frontal left (Fp1, F7, F3 electrode aver‑
age); b) Frontal right (Fp2, F4, F8 electrode average; 
c) Temporal left (T3, T5 electrode average); d) Tempo‑
ral right (T4, T6 electrode average); e) Central (C3, Cz, 
C4 electrode average); f) Parietal (P3, Pz, P4 electrode 
average); g) Occipital (O1, Oz, O2 electrode average) 
(Fig. 2).
Clinical evaluation
Clinical evaluation was carried out by a psychiatrist 
before rTMS treatment and day after the last rTMS ses‑
sion. It consisted of the Montgomery‑Asberg Depres‑
sion Scale (MADRS) (Montgomery and Asberg 1979), the 
Hamilton Depression Rating Scale (HAM‑D) (Williams 
1989) and the Beck Depression Inventory (BDI) scale 
(Beck et al. 1988). General clinical efficacy was based 
on percentage changes of MADRS scale and divided into 
three distinct groups: 1) weak effect (<10% decrease); 
2) medium effect (10%–50% decrease); 3) significant 
effect (>50% decrease) (Fitzgerald et al. 2009b). Remis‑
sion was achieved when MADRS score after the therapy 
was <10 points (Fitzgerald et al. 2006).
Statistical analysis
Statistical analysis was carried out using Microsoft 
Excel 2010 and SPSS statistics v17 software. To measure 
the significance of EEG band power spectrum changes 
after the therapy course, Wilcoxon test for two related 
samples was used. To study the differences of physio‑
logical changes between patient groups and brain ar‑
eas, additional analysis of variance (ANOVA) for repeat‑
ed measures was applied. Within subject variables were 
the measurements before the therapy course and after 
it (Procedure factor). Between subjects factors were 
the Group and brain area. Differences between patient 
groups in clinical test reduction were analyzed using 
One‑Way ANOVA. Correlations between EEG band pow‑
er changes and clinical changes were calculated using 
Pearson correlation coefficient.
RESULTS
After EEG band spectral power changes were aver‑
aged, an increase in delta and theta band power for 
Group 1 patients became apparent (Fig. 3). For the same 
patients, alpha band power had decreased slightly in 
all brain areas except for the left temporal area and oc‑
cipital area. Beta power had increased slightly across 
the brain, except for the right frontal area (Fig. 3). Wil‑
coxon testing showed statistically significant (P<0.05) 
changes in the delta band power in both frontal areas, 
temporal right, central, parietal and occipital areas 
Fig. 2. EEG electrodes averaged according to brain areas. 
Fig. 3. Changes of EEG band power spectrum in Group 1 patients. * P≤0.05 
in Wilcoxon test.
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(Table I). Group 2 patients showed an increase in del‑
ta, theta and alpha band power in all brain areas and 
a decrease in beta band power across the whole brain, 
except for right temporal and occipital areas (Fig. 4). 
However, none of these changes were statistically sig‑
nificant according to the Wilcoxon test (Table I). Group 
3 patients showed an increase in all EEG band powers 
across the whole brain, with the only exception being 
a beta band power reduction in the right temporal area 
(Fig. 5). Statistically significant changes were found in 
the right frontal, parietal and occipital areas in delta 
band power and in the left temporal area for theta band 
power (Table I).
Repeated measures ANOVA’s were carried out to test 
the differences in results between the groups and brain 
areas, as well as a combined therapy effect for different 
EEG bands (procedure factor within groups). This data 
showed that ‘everything combined’ rTMS therapy has 
an effect on delta, theta and alpha band power and sta‑
tistically significant differences can be found between 
different areas in each EEG power band (Table II). There 
are also considerable differences between the groups 
Table I. EEG band power spectrum percentage change averages and standard deviations in all patient groups (Group 1 n=20, Group 2 n=13, Group 3 n=13) 
* P≤0.05 in Wilcoxon test.
Group EEG band
Brain Area
FrontL FrontR TempL TempR Centr Pariet Occip
1
Delta 44.92±24.50*
73.24±
42.53*
63.74±
36.00
65.38±
32.07*
34.59±
17.48*
53.07±
26.09*
90.87±
37.81*
Theta 27.77±26.72
25.05±
22.57
25.85±
19.11
14.52±
22.22
17.95±
22.94
13.55±
20.32
20.03±
20.23
Alpha ‑1.34±14.99
‑2.43±
11.95
23.48±
18.53
‑6.26±
12.98
‑5.53±
13.37
‑3.54±
13.28
16.89±
18.01
Beta 0.52±16.37
‑3.85±
14.02
30.14±
29.76
6.97±
18.52
1.59±
15.35
0.73±
12.60
0.28±
10.93
2
Delta 51.14±41.01
47.87±
30.47
59.62±
42.17
48.10±
33.59
21.42±
21.46
32.01±
23.78
20.61±
23.21
Theta 1.64±10.63
20.88±
24.46
4.75±
19.08
47.22±
54.69
4.92±
12.39
17.41±
16.18
19.16±
17.06
Alpha 3.80±15.96
14.14±
20.73
4.03±
21.54
30.38±
27.43
10.15±
16.77
15.68±
17.01
31.92±
30.50
Beta ‑16.27±10.62
‑12.51±
10.12
‑7.54±
12.41
13.32±
17.95
‑2.08±
11.59
‑0.87±
13.27
10.91±
19.06
3
Delta 48.17±25.39
36.22±
17.61*
203.90±
146.36
41.65±
32.18
36.12±
14.38
45.67±
14.87*
37.26±
15.16*
Theta 36.21±14.24
18.90±
13.68
65.30±
13.74*
32.14±
29.75
41.14±
17.97
36.53±
16.12
40.40±
17.54
Alpha 27.70±19.30
24.01±
17.57
37.68±
28.43
10.67±
27.40
35.54±
17.50
52.43±
43.07
16.73±
9.71
Beta 8.60±11.21
19.92±
14.22
16.65±
17.25
‑8.36±
13.26
20.69±
24.31
19.96±
21.82
18.55±
9.03
Fig. 4. Changes of EEG band power spectrum in Group 2 patients. * P≤0.05 
in Wilcoxon test.
Fig. 5. Changes of EEG band power spectrum in Group 3 patients. * P≤0.05 
in Wilcoxon test.
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in the delta and theta bands (Table II). The later result, 
when taken together with Wilcoxon test findings, sug‑
gests that Group 2 patients had the least physiological 
changes after the treatment, Group 1 had the most no‑
table and widespread increase in the delta band power 
whereas Group 3 had a more sporadic increase in del‑
ta band power and a slight increase in the theta band 
power (Figs 3–5, Table II).
Percentage decreases in clinical test scores show 
a very similar outcome between Group 1 and Group 2 
patients, but Group 3 patients had the largest reduction 
in all three (MADRS, BDI and HAM‑D) clinical test scores 
(Table III). Moreover, when ANOVA’s were applied, the 
HAM‑D test showed statistically significant changes be‑
tween the three groups (Table IV). Pearson correlations 
between the EEG power changes and clinical changes 
failed to show any significant relationships.
DISCUSSION
After rTMS therapy there was a notable tendency 
for a slow EEG wave (delta and theta) power increase 
in all study groups which was not limited to specific 
brain areas. This coincides with several previous stud‑
ies which have showed an increase in slow wave ac‑
tivity after electrophysiological antidepressant thera‑
py (Griškova et al. 2006, Spronk et al. 2008). However, 
these changes do not correlate to a clinical improve‑
ment and tend to show a very basic brain reaction to an 
outside electrical stimulation (Valiulis 2014). Alpha and 
beta power changes were less pronounced and more 
variable. It is important to note that endeavors to find 
specific changes in the alpha band frequency, although 
initially promising from the clinical point of view, also 
failed in a numerous previous studies (Funk and George 
2008, Widge et al. 2013, van der Vinne et al. 2017). 
Group 1 patients displayed the most widespread in‑
crease in delta band power across the brain. This in‑
dicates the largest physiological changes of the three 
groups. The coordinates for stimulation in this group 
were based on Teneback et al. (1999), a SPECT study 
which showed an increase in brain activity in that re‑
gion after rTMS therapy. Our EEG results did not show 
any substantial increase in beta band power in the left 
frontal area, or in any brain region for that matter. 
Table II. Repeated measures ANOVA.
EEG band Factors F P value
Delta
Procedure 20.131 0.0001*
Group 5.982 0.003*
Area 2.316 0.034*
Theta
Procedure 20.74 0.0001*
Group 4.952 0.001*
Area 2.012 0.064
Alpha
Procedure 6.7 0.01*
Group 0.478 0.621
Area 9.112 0.000*
Beta 
Procedure 0.041 0.839
Group 2.651 0.072
Area 3.955 0.001*
Table  III. Average decreases of clinical test scores among the patient 
groups (Group 1 n=20, Group 2 n=13, Group 3 n=13).
Group MADRS BDI HAM‑D
1 54.96% 47.89% 57.52%
2 56.75% 44.14% 56.02%
3 62.9% 55.22% 66.94%
Table IV. One Way ANOVA results for clinical test scores.
Test F P value
MADRS 1.675 0.191
BDI 1.44 0.241
HAM‑D 3.929 0.022*
278 V. Valiulis et al. Acta Neurobiol Exp 2018, 78: 271–280
Group 2 patients showed the mildest increases in 
slow wave EEG band power of all study groups. There 
was also no evidence of activation of the left frontal 
area from the beta band power standpoint. Fitzger‑
ald et al. (2009b), who proposed these coordinates for 
rTMS treatment, did not provide EEG activity change 
measures in his study. However, an fMRI comparison 
highlighted that the Fitzgerald et al. (2009b) target did 
show two times stronger anti‑correlation with subgen‑
ual cingulate cortex activity, when compared to a 5 cm 
anterior to motor cortex standard rTMS target (Fox et 
al. 2012b).
Group 3 patients, whose stimulation targets were 
based on the Fox et al. (2012a) study, produced a mid‑
dling effect when measuring EEG band power chang‑
es. Slow wave power increases were apparent but were 
limited to several brain areas when compared to the 
Group 1 patients. However, like in previous cases, this 
stimulation target provided no benefit when consider‑
ing activity increases via the beta band power rise. 
As stated in the previous literature, overall delta 
power increase is often a consequence of electrophys‑
iological brain stimulation, including both rTMS and 
ECT (Assenza et al. 2015, Griškova et al. 2006, Sackeim 
et al. 1996, Spronk et al. 2008, Valiulis et al. 2012). 
Theoretically, it can be regarded as both a marker of 
neuroplastic processes and brain lesions (Assenza et 
al. 2015). Therefore it makes sense to try and limit its 
manifestation where it is not proved to serve a partic‑
ular clinical benefit.
Patients in Group 1 and Group 2 displayed a 50% de‑
crease in MADRS and HAM‑D clinical test scores. This 
correlates with data from Teneback et al. (1999), the 
study which Group 1 patients rTMS target coordinates 
were based on. Similar decrements in clinical test scores 
were also found in other studies (George et al. 2013, 
Filipcic et al. 2017, Tarhan et al. 2012).
Group 2 patients clinical results in MADRS and BDI 
tests have exceeded previous Fitzgerald et al. (2003) 
rTMS study results: MADRS – 32.2 ± 9.0; BDI – 27.2 ± 10.8 
(Fitzgerald et al. 2003). 
Group 3 patients displayed the largest clinical im‑
provement in MADRS and HAM‑D clinical test scores, 
averaging a 60% decrease. The rTMS target coordinates 
used for this group were based on the Fox et al. (2012a) 
study, which also showed the highest anti‑correlation 
to subgenual cingulate, three times larger than using 
a standard 5 cm anterior to motor cortex rule and 1.25 
larger than when using a target suggested by Fitzgerald 
et al. (2003). Our study findings support the rationale 
of using the left DLPFC point with the highest anti‑cor‑
relation to subgenual cingulate in order to achieve the 
best clinical results, even when calculated in the aver‑
aged MNI map.
No significant correlations were  found between clin‑
ical changes and baseline EEG band power changes. This 
contradicts  the  findings  of  the  ECT  study  conducted  by 
Sackeim et al (1996), which found prefrontal region delta 
power increases, indicative of depressive symptom im‑
provement. However, it conforms to previous rTMS re‑
search, which reported that delta power had no influence 
on the clinical or the neuroplastic improvement (Assen‑
za et al. 2015, Spronk et al. 2008, Valiulis et al. 2012). In 
our study, EEG spectral power changes can be regarded 
as a generalized quantitative measurement of brain reac‑
tion to rTMS therapy, without considerable clinical value. 
Therefore,  in  this  case,  the  rTMS  influence on  slow EEG 
band power seems to be relevant only from the perspec‑
tive of slight changes the different MNI targets have had 
on brain physiology and thus is worth applying when 
small disturbances in brain activity would be considered 
in the choice of rTMS parameters. For a more detailed 
look at clinical rTMS mechanisms, more complex EEG 
algorithms involving more specific and immediate brain 
excitability changes should be used, including standard‑
ized low‑resolution brain electromagnetic tomography 
(sLORETA) (Canali et al. 2014, Noh 2016, Kito et al. 2016).
To summarize, minute changes in rTMS coil place‑
ment when using precision navigation can lead to sig‑
nificant differences in physiological and clinical as‑
pects. This rule can also be applied when using a MNI 
brain model. This supports the use MR‑less MNI based 
neuronavigation for rTMS coil placement in clinical 
practice as a superior option to standard blind or Beam 
F3 methods (Mir‑Moghtadaei et al. 2015, Pommier et al. 
2017). For the best clinical results it is advisable to use 
MNI coordinates ‑38; 44; 26 (Fox et al. 2012a). Howev‑
er, these data should be taken with a slight caution, as 
the patient groups in this study were rather small and 
should be enlarged for the future studies. Also it would 
be beneficial to try and recreate the results using dif‑
ferent rTMS protocols, like the FDA recommended 120% 
motor threshold (MT) intensity 37 minute 10 Hz proto‑
col (O’Reardon et al. 2007) or intermittent theta burst 
stimulation (iTBS) (Huang et al. 2011). It could be pro‑
posed that using longer treatment courses, for example 
six weeks instead of three, may highlight differences 
between groups. For higher relevance and comparison 
purposes in the future it would also be useful to regis‑
ter metabolic changes in the DLPFC and the subgenual 
cingulate, together with more specific EEG changes. It 
would also be interesting to do a direct clinical compar‑
ison of MR‑less MNI based neuronavigated rTMS and 
individual fMRI based neuronavigated rTMS, because 
although complicated and expensive, individual fMRI 
still provides us with individual brain anatomy and the 
possibility to manipulate additional important vari‑
ables like cognitive priming (Luber et al. 2017).
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CONCLUSIONS
1. Lowest physiological changes in EEG power spectrum 
were observed when using ‑46; 45; 38 MNI coordinates, 
highest ‑ when using ‑40; 48; 35 MNI coordinates.
2. Highest clinical gain was observed when using ‑38; 
44; 26 MNI coordinates.
3. Considering both physiological imprint and clinical 
efficacy it is advised to use ‑38; 44; 26 MNI coordinates.
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